Immune therapeutic effect of oral soluble chicken collagen type Ⅱon adjuvant arthritis in rats

Abstract

Abstract: AIM: To investigate the immune therapeutic effect of a small amount of oral soluble chicken collagen type Ⅱ (SCC Ⅱ) on adjuvant arthritis (AA) in rats.METHODS: The ConA-induced the proliferative responses of splenocytes, mesenteric lymph node cells(MLNCs) and peyer' s patche cells(PPCs), IL-1 and TNFαproductions in the supernatants of peritoneal macrophages(PMΥ) and synovial membrane cells (SMCs) combined with the changes of the indices such as ankle joint secondary inflammatory responses, thymus indices and so on in AA rats were assayed or observed.RESULTS: SCC Ⅱ(0.03, 0.30 and 3.00 mg·kg^-1·d^-1, d 12-18, ig) could improve the overreduced ConA-induced splenocyte proliferative responses, but further reduced those of MLNCs and PPCs, inhibited the IL-1 and TNFαproductions in PMΥand SMCs, and ameliorated the secondary inflammatory responses in AA rats.CONCLUSION: A small amount of oral SCC Ⅱ(ig) have the immunotherapeutic effect on AA in rats.

Key words: soluble chiken collagen type Ⅱ, oral immune tolerance, adjuvant arthritis, immunotherapy, lymphocyte proliferative response, IL-1, TNFα, thymus index

CLC Number:

R979.5
R965

LU Yan-Xu, CHEN Min-Zhu. Immune therapeutic effect of oral soluble chicken collagen type Ⅱon adjuvant arthritis in rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(2): 180-183.

References

1 Trentham DE, Dynesius-Treatham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, et al. Effects of oral administration of type Ⅱ collagen on rheumatoid arthritis[J]. Science, 1993 ; 261:1727-30
2 Sieper J, Kary S, Srensen H, Alten R, Eggens U, Huge W, et al. Oral type Ⅱ collagen treatment in early rheumatoid arthritis[J]. Arthritis Rheum, 1996;39(1):41-51
3 Snowden N, Re I, Morgan K, Holt L.T cell responses to human type Ⅱ collagen in patients with rheumatoid arthritis and healthy controls[J]. Arthritis Rheum, 1997 ;40(7):1210-8
4 Seyer JM, Hasty KA, Kang AH.Covalent structure of collagen.Amino acid sequence of an arthrilogenic cyanogens bromide peptide from type Ⅱ collagen of bovine cartilage[J]. Eur J Biochem, 1989;181:159-73
5 Krco CJ, Pawelski J, Harders J, McCormick D, Griffiths M, Luthra HS, et al. Characterization of the antigenic structure of human type Ⅱ collagen[J]. J Immun, 1996;156:2761-8
6 Myers LK, Cooper SW, Terato K, Seyer JM, Stuart JM, Kang AH.Identification and characterization of a tolerogenic T cell determinant within residues 181-209 of chick type Ⅱ collagen[J]. Clin Immunol Immunopathol, 1995 ;75(1):33-8
7 陈敏珠, 魏伟, 张泓, 梁君山.免疫抑制药和免疫增强药实验法[A]. 见:徐叔云, 卞如濂, 陈修, 主编.药理实验方法学[M]. 第2 版.北京:人民卫生出版社, 1991:1208-45
8 Masseyeff RF, Albert WH, Staines NA.Methods of Immunological Analysis:Cell and Tissue[M]. Vol.3.New York:Wiley-VCH, 1993:65-6
9 Gitter BD, Labus JM, Lees SL, Scheetz ME.Characteristics of human synovial fibroblast activation by IL-1β and TNF[J]. Immunology, 1989 ;66:196-200
10 Weiner HL, Friedm A, Miller A, Khoury SJ, Al-Sabbagh A, Santos L, et al. Oral tolerance:Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens[J]. Annu Rev Immunol, 1994 ;12:809-37

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	WANG Xinyu, CHEN Yipeng, MA Yongli, HE Junfei. Study of the improvement effect of "DuZhong-DangGui" on osteoarthritis rats via regulating NLPR3 inflammasome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 751-757.
[3]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[4]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[5]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[6]	LI Wei, HU Jiali, WANG Kai, HE Yijing. Research progress and prospect of immunotherapy in the treatment of melanoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1053-1064.
[7]	MIN Hang, GUO Mengran, YE Yue, XU Xiaoshuang, ZHEN Donghu. Research progress of thyroid dysfunctions during treatment with immune-checkpoint inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 223-229.
[8]	ZHAO Quanming, YANG Yang. Progress in drug therapy for advanced triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 475-480.
[9]	TAI Yu, ZHANG Zixuan, ZHANG Lingling. Advances in the management of psoriatic arthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1395-1407.
[10]	CHANG Xiangxiang, WEI Zhongling, ZHENG Xingyuan, LI Huimin, HUANG Laiquan. Progress in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 107-116.
[11]	ZHANG Kaiting, CHEN Naihan. Development of therapeutic biologics in cancer treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 32-43.
[12]	CHENG Run, DING Wenxi, YAN Shangxue, WEI Wei. Human umbilical cord-derived mesenchymal stem cells alleviate adjuvant arthritis by regulating macrophage in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1335-1340.
[13]	LV Xiaojuan, TANG Weihong, WANG Huiting, WANG Zhongmin, GUAN Minchang, LI Haifeng. Efficacy and safety analysis of fiberoptic bronchoscopy combined with methylprednisolone in children with RMPP [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1040-1046.
[14]	ZHENG Shuang, FU Qinlei, ZHOU Lingping, PENG Chuanpeng, XU Honglei. Study on interleukin-17A during early inflammatory response in mice with LPS-induced acute lung injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 148-153.
[15]	ZHANG Xiaoying, WANG Kang, WU Sha, GUO Peng. Association analysis of low dose olanzapine in controlling mental symptoms of NMDAR encephalitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1292-1296.